CT 101a
Alternative Names: CT-101-aLatest Information Update: 25 May 2023
At a glance
- Originator Shanghai Zerun Biotechnology Co
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Acute myeloid leukaemia
Most Recent Events
- 03 Apr 2023 Shanghai Zeke Biotechnology in collaboration with Zhejiang University terminates a phase I trial in Acute myeloid leukaemia (Recurrent, Refractory metastatic disease) in China (Parenteral) as a new study is planned to replace the current study due to IP upgrade(NCT05256277)
- 28 Dec 2021 Phase-I clinical trials in Acute myeloid leukaemia (Recurrent, Refractory metastatic disease) in China (Parenteral) (NCT05256277)